-
Posted by
Two Blokes Jul 17 -
Filed in
Stock
-
4 views
Sarepta's turnaround is just beginning, with decisive management actions like layoffs boosting confidence and saving $100 million annually. The market had priced in the worst for Elevidys, but the FDA's black box warning was a positive surprise, opening potential future catalysts. Sarepta is not a one-trick pony; upcoming clinical results for SRP-9003 and other pipeline assets add upside optionality.
